Themis Medicare Ltd has announced the approval of its antiviral drug VIRALEX by the Drug Controller General of India (DCGI). As per the results of double blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate Covid-19 patients.
VIRALEX is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate and adaptive immunity and strengthens the bosy’s defence response to viral infections.
At around 1:49 PM, Themis Medicare was trading at Rs1,020.05 apiece up by Rs2.7 or 0.27% on Sensex today.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
